Dosing and uses of OptiPranolol (metipranolol ophthalmic)
Adult dosage forms and strengths
ophthalmic solution
- 0.3%
Open-Angle Glaucoma
1 gtt in affected eye(s) BId
Pediatric dosage forms and strengths
Safety & efficacy not established
OptiPranolol (metipranolol ophthalmic) adverse (side) effects
Frequency not defined
Ocular
- Burning sensation in eye
- Blepharitis
- Blurred vision
- Light intolerance
- Uveitis
Systemic
- Similar to systemic beta-blockers (bradycardia, aggravation of CHF, asthma, caution in diabetes as may mask signs of hypolgycemia, nightmares, impotence, tiredness, etc)
- Reduction of systemic side effects by putting finger in corner of eye (occluding punctum) or by gentle eyelid closure (without opening & closing lid) for 3 min
Warnings
Contraindications
Hypersensitivity
Asthma, uncompensated CHF, severe COPD, symptomatic sinus bradycardia, >1st degree AV block, cardiogenic shock
Pregnancy and lactation
Pregnancy category: C
Lactation: use caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of OptiPranolol (metipranolol ophthalmic)
Onset: 30 min
Duration: 24 hr
Maximum effect: 2 hr
Mechanism of action
Nonselective beta-blocker
